International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 012-015
A COMPERATIVE STUDY OF THE EFFICACY, COST AND ADVERSE EFFECTS OF THE THIRD GENERATION ANTIEMETIC AGENTS IN CANCER PATIENTS
DENİZ YAMAÇ1, GÖKHAN ÇELENKOĞLU1, UĞUR COŞKUN1, ABDULREZZAK ABUBAKAR1, NAZAN GÜNEL1
Gazi University Medical School, Department of Medical Oncology
Keywords: anti-emetic agents, cancer, efficacy, cost, adverse effects
The aim of this study was to compare the efficacies, adverse effects and cost- effectiveness of the commonly used serotonine receptor antagonists (SRA) ondansetron, tropisetron and granisetron at standard doses. Of the 97 patıents given chemotherapy at our center for various tumours, 31 of them were treated with granisetron, 33 with tropisetron and 33 with ondansetron. Thirty-three (26.8%) patients received cisplatin-based chemotherapies. The grading of nausea and vomiting was made according to the WHO criteria. The patients were evaluated for acute onset emesis with in the first 48 hours and following three days for delayed emesis during the first cycle of treatment. They were also evaluated on the fourth treatment cycle. No significant difference was observed between the efficacies of the three drugs (p>0.05). Headache and constipation were the most frequently encountered adverse effects. Constipation was found higher for granisetron compared to the other two drugs (p=0.026). When the cost was estimated based on the recommended daily doses, ondansetron increased the cost of treatment to 2-3 fold compared to granisetron and tropisetron because of the need for their three times daily doses. Even if all drugs have similar efficacy in this study, tropisetron was found to be more advantageous than the other two drugs when side effects and cost of treatment were considered.
DENİZ YAMAÇ1, GÖKHAN ÇELENKOĞLU1, UĞUR COŞKUN1, ABDULREZZAK ABUBAKAR1, NAZAN GÜNEL1
Gazi University Medical School, Department of Medical Oncology
Keywords: anti-emetic agents, cancer, efficacy, cost, adverse effects
The aim of this study was to compare the efficacies, adverse effects and cost- effectiveness of the commonly used serotonine receptor antagonists (SRA) ondansetron, tropisetron and granisetron at standard doses. Of the 97 patıents given chemotherapy at our center for various tumours, 31 of them were treated with granisetron, 33 with tropisetron and 33 with ondansetron. Thirty-three (26.8%) patients received cisplatin-based chemotherapies. The grading of nausea and vomiting was made according to the WHO criteria. The patients were evaluated for acute onset emesis with in the first 48 hours and following three days for delayed emesis during the first cycle of treatment. They were also evaluated on the fourth treatment cycle. No significant difference was observed between the efficacies of the three drugs (p>0.05). Headache and constipation were the most frequently encountered adverse effects. Constipation was found higher for granisetron compared to the other two drugs (p=0.026). When the cost was estimated based on the recommended daily doses, ondansetron increased the cost of treatment to 2-3 fold compared to granisetron and tropisetron because of the need for their three times daily doses. Even if all drugs have similar efficacy in this study, tropisetron was found to be more advantageous than the other two drugs when side effects and cost of treatment were considered.